Outsourced Pharma White Papers

  1. Breaking The Either-Or Paradigm Of CDMO Selection 8/13/2020

    Choosing a contract development and manufacturing organization (CDMO) often requires “either-or” tradeoffs that divide the candidate companies into polarities of size, location and services offered. 

  2. Assessing The Financial Impact Of Translational Pharmaceutics® 3/3/2022

    Examine an innovative approach to accelerating drug development, and learn the savings to drug developers from applying the approach across the industry portfolio of investigational drugs.

  3. Considerations In Formulation Development Of Injectable Solutions 2/8/2022

    Injectable solutions offer an alternative to oral dosage form due to fast onset, reproducible PK/efficacy profile, high bioavailability, and suitability of administration under hospital setting.

  4. Biotech's Mirrored Universe: Predictive Engineering And Digital Twinning 7/8/2020

    The biotechnology industry now can harness advanced engineering techniques that have helped save astronauts, save energy, and save countless millions of dollars.

  5. Addressing The Challenge Of Scalability In Viral Vectors 8/10/2021

    MilliporeSigma has developed a wide range of solutions to facilitate the delivery of gene therapy by addressing the challenges related to viral vector manufacture and scale-up.

  6. Rational Design & Development Of Lipid- Filled Hard Capsules 1/26/2022

    With the increasing percentage of water-insoluble or low permeable new therapeutic entities among drug pipelines, lipid-based drug delivery systems have become an important tool for formulation development.

  7. Age-Appropriate Pediatric Formulation Development 1/27/2022

    There is a significant variability in the pharmacokinetics of the same drug and dosage form between pediatric and adult populations, and the factors impacting drug bioavailability are different in children.

  8. Challenges And Practical Solutions For Switching To Prefilled Syringes For Injectables 9/1/2020

    To achieve the benefits of moving a final product presentation from vials to prefilled syringes, it is important to understand the challenges during this solution as well as practical solutions.

  9. Mitigating Risk Of Validated Analytical Procedure Failures When Upgrading Or Replacing LC Assets 2/1/2022

    Principles like instrument Quality by Design (iQbD) can help one understand the risks of validated analytical procedure performance when older workhorse LC instruments are replaced with newer instruments.

  10. The Biotech And The CDMO: The Case For An Early Partnership 10/2/2020

    Biotech investigators can’t possibly know everything required to move their drug candidate from the lab bench to the marketplace. Accepting that reality is the first step toward finding a strategic partner.